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AbstrACt
Objectives To identify which information items potential 
participants and research nurses rank as the most 
important, and the reasons for this, when considering 
participation in a randomised controlled trial.
Design Q-methodology approach alongside a think-
aloud process. Using a vignette outlining a hypothetical 
trial, participants were asked to rank statements about 
informational items usually included in a participant 
information leaflet (PIL) on a Q-grid, while undertaking a 
real-time think-aloud process to elicit the underpinning 
decision processes. Analysis of quantitative data was 
conducted using descriptive statistics and qualitative data 
was coded using content analysis.
Participants 20 participants (10 potential trial 
participants and 10 research nurses).
setting UK-based participants.
results Ten research nurses and 10 potential trial 
participants provided data for the study. Both stakeholder 
groups ranked similar statements in their top three 
most important statements, with ‘What are the possible 
disadvantages and risks of taking part?’ featuring in 
both. However, considerable variability existed between 
the groups with regard to their ranking of statements of 
least importance. Participants identified that sufficient 
information to make a decision was secured using around 
14 items. Participants also identified other items of 
importance not routinely included in PILs.
Conclusions This study has provided a unique insight 
into how and why different trial stakeholder groups rank 
informational items currently contained within PILs. These 
results have implications for those developing future PILs 
and those who develop guidance on their content; PILs 
should focus most on the information items that potential 
trial participants want and need to make an informed 
choice about trial participation.
bACkgrOunD  
Research is an important part of the develop-
ment of medicine, including the development 
of new treatments, services and technologies. 
In particular, randomised controlled trials 
(RCTs) are considered the gold standard for 
evaluating the efficacy and safety of new treat-
ments and effectiveness of existing interven-
tions.1 2 Central to the successful delivery of 
RCTs are the participants who agree to take 
part. Strict regulations and legislation are in 
place governing the process of approaching 
and consenting potential participants to take 
part in order to ensure that their rights and 
interests are protected.3 4 
Seeking informed consent (usually 
prospectively) from potential participants is a 
prerequisite for their inclusion within almost 
all RCTs. A printed participant information 
leaflet (PIL) is a key document that aims to 
support the informed consent process. A PIL 
should provide the reader with clear and 
easy-to-understand information.3 4 Regula-
tory bodies have provided guidance on the 
inclusion of content which they deem to be 
required to ensure that the consent given 
is ‘informed’.3 4 In addition to providing 
information about the proposed research, a 
PIL often provides a mechanism to support 
conversations about the trial between the 
potential participant and the researcher 
and/or health professional, allowing the 
participant the opportunity to ask any ques-
tions important to their decision and discuss 
the research in more detail.5 However, the 
recruitment and consent process for some 
trials is such that a conversation between a 
researcher and potential participants is less 
likely (eg, postal or online recruitment) and 
strengths and limitations of this study
 ► This study is one of the first to provide evidence on 
the importance of informational items prescribed in 
the regulatory guidance with regard to making an 
informed choice about randomised controlled trial 
participation to potential trial participants and re-
search nurses.
 ► Our study used a novel methodology (Q methodol-
ogy) to obtain rankings of informational items for 
participant information leaflets from different trial 
stakeholder groups, namely potential trial partici-
pants and research nurses.
 ► The solely UK-based self-selecting sample may hold 
different views to those in other countries with dif-
ferent social norms and cultures.
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here the written information may have more influence. 
Ideally, the aim of the PIL should be to provide informa-
tion to assist the participant in making a decision as to 
whether to take part in a trial or not.5
In the UK, current guidelines for PILs are set out by 
the Health Research Authority (HRA), the body estab-
lished to ensure that the interests of patients who take 
part in research are protected and also to promote good 
quality research in the UK. The HRA’s guidance lists 36 
topic areas for suggested inclusion in PILs for research.5 
These 36 items were informed by legislation on informed 
consent for research and cover aspects such as: the 
purpose of the research; potential benefits and risks; the 
right to refuse or withdraw; and treatment alternatives.3 4
At present there is a lack of evidence about whether the 
topic areas identified in the HRA guidelines are perceived 
as important, or useful for decision making, from the 
participants’ perspective. A systematic review by Kirkby 
et al6 emphasised the lack of empirical evidence to support 
the items included in the HRA guidance with regard to 
what topics participants want to know about when consid-
ering taking part in research (not just trials). Further-
more Armstrong et al7 suggest that PILs are written with 
the primary focus being regulatory review as opposed 
to a principal role in supporting participants’ decision 
making.
Existing research also suggests that PILs may not be 
fit for purpose and that trial participants have a lack 
of understanding about key aspects of the trial.8 9 This 
includes those participants who have consented and been 
recruited to trials and those who are considering partic-
ipating in trials.10 To date, existing research on PILs for 
trials has tended to focus on structure: redesigning and 
rewriting to improve readability and understanding and 
exploring easy-to-read consent statements versus standard 
consent statements or short versus long PILs.8–10 The 
majority of this existing research has not questioned the 
information content (specified by the regulatory guide-
lines) that should be contained in PILs from the perspec-
tives of potential participants and/or other stakeholders 
engaged in the trial consent process.
Aside from the participants themselves, research 
nurses (RNs) play a vital role in clinical trial delivery 
(certainly in the UK), particularly during the informed 
consent process. The role of an RN is that of the patient 
advocate, supporting any potential research partic-
ipant throughout the research process. As RNs are 
routinely involved in seeking informed consent from 
potential research participants, they also have a unique 
insight into the topic areas and questions that may arise 
during the informed consent conversation. However, 
whether the informational items RNs perceive as being 
important to support decision making when discussing 
trials aligns with desires of potential participants is not 
known. Understanding whether these groups are similar 
or differ in their perspectives could provide important 
insights to improve the informed consent process for 
RCTs.
The aim of this study is to identify and assess which of 
the prescribed information items potential participants 
and RNs rank as the most important, and the reasons for 
this, when considering participation in a phase III RCT. A 
related objective was to explore whether there were any 
differences in how the information is ranked between the 
different groups.
MethODs
This research study used a Q-methodology approach to 
determine the relative importance of informational items 
presented in PILs to potential trial participants (PTPs) 
during the informed consent process. Q-methodology 
uses a mixed methods approach that aims to identify 
shared views, opinions, beliefs and attitudes across a 
population, forcing people to trade off different dimen-
sions and rank items in order of importance.11 The Q-sort 
technique provides participants with a question/topic 
of interest and a set of associated relevant statements 
linked to the topic (the Q-set), which are then ranked 
by the participant according to what they feel are most 
and least important from their perspective in relation to 
the question posed by the researcher. The participant 
places statements onto a specialised grid (known as a 
response grid) and is asked to provide justification for 
placement through a ‘think-aloud’ process. Here, partici-
pants verbalise in real-time the thought processes under-
lying their choice of where to place each statement on the 
response grid.
In full Q-methodology, one is usually concerned with 
trying to identify how viewpoints cluster together; this 
is usually undertaken through the use of formal statis-
tical Q-factor analysis.11 In this study, however, we were 
more interested in the differences/similarities within and 
across the two stakeholder groups and the reasons why, 
so we did not proceed with the full factor analysis stage. 
We rather used descriptive statistics to summarise the 
perceived importance of items within stakeholder groups 
and further between stakeholder groups. As we did not 
use the full Q-methodology, we have described our study 
as using a Q-methodology approach.
scope of study
A vignette (see online supplementary file 1) was devel-
oped, which described a hypothetical phase III RCT of 
two treatments for a chronic condition, to help partici-
pants contextualise the Q-sort statements and enable 
them to provide their subjective opinions and points of 
view. Two vignettes were prepared (based on the same 
trial example but framed to the perspectives of the two 
stakeholder groups). The PTP group were asked to 
consider ‘What information would be important to you when 
making a decision to take part?’ The RN group were asked, 
‘What information would be important to potential participants 
when making the decision to take part?’
Development of the Q-set
The Q-set of statements were developed using three 
sources of information: (1) the HRA guidance on 
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‘Consent and Participation Information Sheets’5; (2) 
a published systematic review that identified empirical 
evidence to support what potential research participants 
want to know about research when considering partici-
pation6; and (3) a published scoping exercise that had 
identified desirable features for a centralised public 
information resource about clinical trials.12 To avoid 
duplication of concepts, the development of the Q-set 
statements started with a mapping exercise where the 
individual informational items identified by Kirkby et al6 
and Langston et al12 were mapped onto the list specified 
in the HRA guidance.5 Given the generic focus of our 
vignette, a number of the more specialised HRA items 
(those which cover the particular circumstances of: radi-
ation, pregnancy and breast feeding, young people and 
pregnancy, genetic research, screening and exclusion, 
adults not able to consent for themselves and commer-
cial exploitation) were excluded from consideration. This 
resulted in a final total of 32 statements, which formed 
the Q-set.
A list of scripted prompts (related to each statement) 
were also developed to ensure consistency in response 
where further information or clarification was required 
by participants regarding what was meant by a particular 
statement allowing explanations to be standardised across 
interviews.
A 32-element Q-grid was then developed following a 
quasinormal distribution as per Q-methodology stan-
dards (see online supplementary file 2). The grid was 
split into three areas: columns 1–3 of the Q-grid represent 
the ‘more important’ items; columns 4–6 of the Q-grid 
represent ‘neutral’ items; and columns 7–9 of the Q-grid 
the ‘less important’ items. Statements were given a refer-
ence number and laminated. Three pilot Q-sorts and 
interviews were conducted to ensure comprehensiveness 
of the statements and prompts and ensure no overlap or 
duplication between statements.
sample size
For the purpose of this project, a sample size of 20 partic-
ipants, 10 from each trial stakeholder group, was deemed 
appropriate. Typically, Q methodology uses relatively 
small samples of participants and the literature suggests 
that a 2:1 ratio of statements to participants (irrespec-
tive of stakeholder group) is favoured as a minimum. 
For example, a study with 40 statements would have 20 
participants as a minimum. As this study has 32 state-
ments, following the principle above, we would require 
an overall sample of approximately 16 participants in 
total as a minimum.11
Participants
Potential trial participants
PTPs were identified from the SHARE register. SHARE 
is a register of people who have an interest in taking part 
in research, developed by National Health Service (NHS) 
Research Scotland.13 For the purposes of this project, 
people who lived within the NHS Grampian (NHSG) area 
(the health board area of the lead researcher to allow 
face-to-face Q-sorts to be undertaken) were identified 
and invited in line with the current SHARE application 
process. The details of 17 potentially interested partici-
pants were provided to the research team by SHARE. All 
17 potential participants were contacted by the researcher 
by telephone to arrange a convenient time for a Q-sort 
interview. Following this conversation, 10 participants 
expressed interest (seven declined further information) 
and were sent postal confirmation of the appointment 
time and a PIL for the Q-methodology study (available 
from the researchers on request). At the Q-sort inter-
view, participants were provided with an opportunity to 
discuss the research and have any questions answered 
before completing a consent form and taking part in the 
card sort interview. All participants included in the study 
provided written consent.
Research nurses
RNs were sought from the NHSG RN pool. Study infor-
mation was provided to the NHSG RN manager who 
disseminated an invitation and the PIL relating to the 
study to the NHSG RNs email distribution list (n=100). 
Details of 12 interested nurses were received. Inter-
ested participants were asked to contact the researcher 
by email or telephone to arrange an appointment for a 
Q-sort interview. Following this, participants were sent an 
email with confirmation of the appointment time. At the 
Q-sort interview, RNs were provided with an opportunity 
to discuss the research project and have any questions 
answered before completing a study consent form and 
taking part in the Q-sort interview. All provided written 
consent.
Data collection
One author (KI) conducted the Q-sort interviews between 
August 2015 and March 2016. All interviews were face-to-
face and conducted at the University of Aberdeen. Q-sort 
interviews were audio recorded. At the start of the inter-
view participants were presented with the trial vignette 
and the 32 statements (in random order each time) and 
asked to sort the statements into three initial piles: (1) 
those that they thought were important when considering 
whether to take part in the hypothetical phase III RCT; 
(2) those which they thought were less important; and 
(3) those which they had a neutral view about. Once the 
cards had been sorted into three piles, the participant 
was shown the Q-grid, given an explanation of how to 
place the cards onto the grid and asked to start placing 
them (ie, ranking in order of priority) while at the same 
time providing verbal explanation (‘think aloud’) as to 
why they were placing statements in a particular square 
of the grid. If participants were unsure of the meaning 
of any of the statements in the Q-set, the researcher used 
standardised prompts, described earlier, to aid under-
standing. On completion of the grid, the PTP group were 
asked if they felt any information was missing from the 
statements and also to indicate at which point on the grid 
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they would be able to make a decision about participation 
in the hypothetical RCT.
At the end of the task, participants were asked to 
complete a demographic details form and thanked 
for their participation. A photograph was taken of the 
completed response grid and a paper copy of the response 
grid completed by the researcher. Audio files were tran-
scribed verbatim and anonymised accordingly.
Data analysis
Descriptive statistics
Data were collated across individual participants 
within each stakeholder group and used to calculate 
the following for each of the 32 items: (1) the median 
importance score (ie, the median position given by 
participants for that statement which could range from 
1 to 9 (the higher the median importance score the less 
important the statement is that is, 1 most important, 9 
least important); (2) the IQR around the median impor-
tance score; and (3) the range of scores for each item by 
group. These summary statistics allowed the statements to 
be ordered from most to least important for each of the 
trial stakeholder groups. The overall ranking of the state-
ments was based on the median value; however, in the 
case where the median value was the same for more than 
one statement, the IQR was considered (and if necessary 
the range) in order to determine order. Differing views 
on individual items between the PTP and RN group were 
defined as ‘discordant’ if they exhibited a difference in 
the median rankings of ≥2 points between the groups. 
The PTP group were asked how many information cards 
they would require to make a decision about trial partic-
ipation. These data were collated, and medians and a 
range were calculated.
Qualitative analysis
Transcripts were read and reread to ensure complete 
familiarity with the transcripts. Text within the transcripts 
was coded by Q-set statement number using a content 
analysis approach.14 Quotes were selected that illus-
trated reasons for ranking for the overall group majority 
or any outliers. Transcripts from the RNs and potential 
participants were initially considered separately but were 
then systematically compared for areas of agreement or 
disagreement.
Patient involvement
Patients were not involved as research partners in the 
design, data collection or data analysis phases of this 
research. A patient research partner (JE) was involved 
in the drafting of the manuscript for publication. Partic-
ipants in the research will be offered a summary of the 
results of the study.
Approvals
All interview participants provided their signed consent, 
which included consent for anonymised quotes from 
their interviews to be published.
results
Participant characteristics: PtPs
Seventeen PTPs were approached through the SHARE 
database, and 10 consented to take part in this research 
project. The 10 PTPs had a mean age of 49.4 years (range 
34–73 years). Five men and five women were interviewed; 
men had a mean age of 59.2 years, and women had a 
mean age of 39.6 years. Education levels varied between 
this group—four participants had secondary education 
(eg, O level, General Certificate of Secondary Educa-
tion (GCSE) and Highers); one of these four had also 
completed an apprenticeship. The remaining six had 
completed higher education (eg, a degree). Seven PTPs 
had no previous experience of research. Q-sort interviews 
took an average of 38.7 min (range 23.6–62.3 min).
Participant characteristics: rns
One hundred NHSG RNs were invited through the RN 
manager email distribution list, and 12 consented and 
took part in this research project. Data from 10 of the 12 
RNs is presented in the analysis due to an early change in 
the study documentation affecting the data from two of 
the participants. The 10 RNs whose data were included 
in the analysis were all female and had a mean age of 
40.4 years (range 28–59 years). All had at least higher 
education (eg, a degree) and the range of research they 
had worked on varied from observational studies to 
Clinical Trial on an Investigational Medicinal Products 
(CTIMPs). Q-sort interviews took an average of 42.2 min 
(range 24.1–62.2 min). Summary characteristics of study 
participants are presented in table 1.
ranking of statements
Overall ranking summaries are presented for the poten-
tial participant group (table 2) and RN group (table 3).
Table 1 Summary participant characteristics
Potential trial 
participants Research nurses
Age (median; 
range
49.4 years
(34–73 years)
40.4 years
(28–59 years)
Gender (% 
female)
5 (50) 10 (100)
Education (%) Secondary 30 Secondary
Apprenticeship 10 Apprenticeship
Higher 60 Higher 100
Involvement in 
research
Three previously 
participated in 
research
CTIMPS
Interventional non-
CTIMPS
Observational
Q-sort interview
(median 
min:sec)
38.7 min (range 23.6–
62.3 min)
42.2 min (range 24.1–
62.2 min)
CTIMPs, Clinical Trial of an Investigational Medicinal Products.
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top-ranking items: the most important information
There were several similarities between the RN and PTP 
groups in terms of the statements that they ranked as 
most important. PTPs ranked ‘What are the possible side 
effects of trial treatment?’ as their most important item, 
with RNs ranking it as fourth. Some of the reasons cited 
by PTPs for this being the most important related to their 
own personal safety, not being hurt and knowing the types 
of events they should report to the trial team
… if it was going to be taking medication or if it was 
going to be some other sort of new treatment, it 
would be important to know as much as you could 
about what possibly might go wrong with it, so 
that you can protect yourself. (PTP20 – ranked in  
column 1)
RNs also reported trial participants want to know 
about side effects but that, in their perspective, this only 
mattered to a small number they ranked it lower.
There has been a very few handful who have asked me 
for some data of how many percent have had side-ef-
fects or how many in the overall study how many – I 
have had questions but it’s just that it’s such a small 
rare quantity of people. (RN5 – ranked in column 4)
Table 2 Potential trial participants: ranking of statements (from most to least important)
Statement Rank Median IQR Range
What are the possible side effects of trial treatment? 1 (most important) 2 1.5–3.5 1–5
What are the possible disadvantages and risks of taking part? 2 2 2–3 1–4
What will I have to do? 3 2.5 2–4 2–5
What are the possible advantages of taking part? 4 3 2–4 2–5
What is the treatment that is being tested? 5 3 2–4 1–7
What will happen to my treatment when the research study 
stops?
6 3 2.5–4 2–4
How will my treatment be decided? 7 3.5 3–5.5 2–7
What will happen to me if I take part? 8 4 1–5.5 1–7
What is the purpose of this study? 9 4 2–4 1–7
Will I know what treatment I am on? 10 4 3–7.5 3–9
Has the scientific quality of study been checked? 11 4.5 3–5.5 2–8
What are the alternatives for treatment? 12 4.5 3–6 3–7
What happens if relevant new information becomes available? 13 5 3–6 1–7
Will my general practitioner be told? 14 5 4–6.5 4–4
What will happen to the results of the study? 15 5 4–6.5 3–7
Who has overall responsibility for the study? 16 5 4.5–5 4–7
Who has approved the study? 17 5 5–6 2–7
Do I have to take part? 18 5.5 3.5–8 2–9
Who could I contact for further information? 19 5.5 4–6 4–7
Who will have access to my data? 20 5.5 4.5–7 3–7
What if I have a complaint? 21 5.5 5–7.5 4–9
Why have I been invited? 22 6 3.5–7.5 2–8
Will my taking part in the study be kept confidential? 23 6 4.5–7 3–8
Will information from my existing medical records be 
accessed?
24 6 4.5–7 2–8
What will happen if I don't want to carry on with the study? 25 6 5–6.5 4–7
How have patients and the public been involved in the design 
of the study?
26 6 5–7 4–7
How will data be stored and disposed of? 27 6 5.5–7 4–8
What is involved in the consent process? 28 7 5–8 4–9
Who is funding the research? 29 7 5.5–8 3–9
Will expenses be reimbursed? 30 8 5.5–8 5–8
Will there be any impact on any insurance policies? 31 8 5.5–8.5 3–9
Will I receive any payments for taking part? 32 (least important) 8 6.5–8.5 6–9
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With regard to the second most important item, PTPs 
ranked ‘What are the possible disadvantages and risks of 
taking part?’ with RNs ranking it in first place. Although 
the position of the ranking is different between the 
groups the reasons provided were similar and related to 
benefits for self, while weighing up any potential negative 
consequences.
Well, I think I’d have to hear them both and then 
decide, you know? So, say, for example, you said with 
the advantages, it could improve your condition and 
the disadvantages were… you might get headaches 
with it or something, so it depends on the strengths 
of both. (PTP18 – ranked in column 2)
I think it’s kind of almost maybe a sort of selfish kind 
of individual kind of thought of what does this mean 
for me rather than looking at the bigger picture of 
what the study is actually about. (RN1 – ranked in 
column 2)
PTPs ranked ‘What will I have to do?’ as the third most 
important statement highlighting the importance of 
knowing what would be expected of them, whereas RNs 
ranked this item in position six but with similar reasoning 
regarding expectations.
… just to make sure it wasn’t going to involve too 
much from what would be the normal sort of scenario, 
Table 3 Research nurses: ranking of statements (from most to least important)
Statement Rank Median IQR Range
What are the possible disadvantages and risks of taking part? 1 (most important) 2 2–4 2–4
What is the purpose of this study? 2 2 2.5–4 1–6
What are the possible advantages of taking part? 3 2.5 2–3.5 1–4
What are the possible side effects of trial treatment? 4 2.5 2–4 1–7
What is the treatment that is being tested? 5 3 1.5–4 1–4
What will I have to do? 6 3 2.5–4 2–4
Do I have to take part? 7 3 2.5–4.5 2–6
What will happen to me if I take part? 8 3 3–3.5 1–4
How will my treatment be decided? 9 3 3–4.5 2–5
Why have I been invited? 10 3.5 1–4 1–7
What are the alternatives for treatment? 11 4 3–4 2–5
Will I know what treatment I am on? 12 4 3–5 2–5
What will happen to my treatment when the research study stops? 13 4.5 4–5 3–5
What happens if relevant new information becomes available? 14 5 4–6.5 3–7
What will happen if I don’t want to carry on with the study? 15 5 4.5–5 3–7
Will information from my existing medical records be accessed? 16 5 5–6 5–8
Will there be any impact on any insurance policies? 17 5 5–6 4–7
Will expenses be reimbursed? 18 5 5–6.5 4–7
Will my taking part in the study be kept confidential? 19 5.5 4–6 4–7
Will my general practitioner be told? 20 5.5 4–6.5 3–7
What is involved in the consent process? 21 6 4.5–6 2–7
Who will have access to my data? 22 6 5–6.5 5–7
Will I receive any payments for taking part? 23 6 5–6.5 5–8
Who could I contact for further information? 24 6 5–7 4–7
What will happen to the results of the study? 25 6 5.5–7 5–7
What if I have a complaint? 26 6.5 5.5–7 5–7
Who has overall responsibility for the study? 27 7 5.5–7 5–8
How will data be stored and disposed of? 28 7 5.5–8 5–8
Who is funding the research? 29 8 7.5–9 7–9
Has the scientific quality of study been checked? 30 8 8–8.5 7–9
How have patients and the public been involved in the design of the 
study?
31 8 8–8.5 6–9
Who has approved the study? 32 (least important) 8 8–9 7–9
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make sure that I wasn’t committing to something that 
maybe… on top of something that might already 
be quite stressful or is going to add a lot of work or 
time… (PTP7 – ranked in column 3)
… with a chronic condition that patient’s not that 
concerned about the end point of the study, just 
about getting an option for treatment. So I think they 
would actually want to know ‘what will I have to come 
in and contribute, how much work will it be?’ (RN7 – 
ranked in column 4)
The second and third most important items ranked by 
RNs did not feature in the PTPs top three. RNs ranked 
‘What is the purpose of this study?’ in position number 
2, stating the importance of highlighting to potential 
participants how the trial is relevant to them. However, 
PTPs ranked this statement in position number 9; the 
rationale being this statement has less to do with them as 
individuals. These items exhibited the biggest difference 
between groups in terms of items in each group’s top 3, 
which is not surprising when considering the individual 
groups interpretations.
I feel this is the most important to let the patients 
know what we are trying to do, what’s the purpose of 
doing the study to begin with. A bit of explanation as 
to why we’re doing it in the first place. (RN3 – ranked 
in column 1)
‘What the purpose is?’ probably just to know whether 
it was something they were going to continue doing, 
or if it was just a trial and a kind of… guinea pig situ-
ation, just to see what happened. I suppose, knowing 
that if you could help other people with a similar con-
dition, it might sort of give you the incentive to help 
or be part of it. (PTP17 – ranked in column 4)
In third place, RNs ranked ‘What are the possible advan-
tages of taking part?’ as important, while PTPs ranked 
this statement as their fourth most important statement. 
Although in slightly different overall position, both RN 
and PTP gave similar reasons for their ranking, linked to 
balancing and weighing up of consequences.
So it may be that this drug won’t be available to them, 
it’s not going to be available to them if they don’t take 
part so it’s important that they know that, that there 
may be an advantage in the sense that they won’t have 
access to this drug. (RN4 – ranked in column 4)
I would want to know the worst case scenario and then 
I’d probably ask after that what would be the benefits, 
because I would assume that there were going to be 
benefits, I guess. (PTP7 – ranked in column 3)
lowest ranking items: the least important information
PTPs ranked ‘Will I receive any payments for taking 
part?’ as the least important statement in position 32 
with reasoning related to expectations of volunteering 
not requiring payment and opportunities for treatment 
outweighing remuneration. In comparison, RNs ranked 
this in position 23 with some highlighting this as a 
potential incentive for patients to participate or provide 
outcome data.
Well, I volunteered so I don’t expect to get paid for 
volunteering to do something. That’s why I say that’s 
the least important. (PTP13 – ranked in column 9)
I don’t think patients are also that concerned about 
being reimbursed for taking part in the study. I think 
the benefits that they may get from the study, I would 
say outweigh… especially if it’s a chronic condition 
that they’ve got, that they’ve lived with for a long 
time, that I think that if they see a glimmer of hope 
that that’s more important than maybe getting pay-
ment. If, though, the study was very… sorry, had a 
number of visits, I think then that would be where the 
payments would then move for me. (RN4 – ranked in 
column 5)
From the ranking summary, PTPs ranked ‘Will there be 
any impact on any insurance policies?’ as the second least 
important statement in position 31 and most did not see 
the relevance of this item for the decision. RNs ranked 
this in position 17 with some citing reasons for particular 
cohorts as influencing their placement.
… I don’t know, maybe I’m a bit blasé about that as 
well. That just didn’t come into my head at all. Even 
at the moment I’m thinking… no just wouldn’t affect 
me one little bit… I think even if I was given an infor-
mation leaflet on the impact on insurance policies I 
probably wouldn’t even read it, to be honest. (PTP7 
– ranked in column 9)
And insurance policies, I think that’s important be-
cause not all of the patients you have will be in their 
eighties and not having holidays anymore. So in-
surance is important for the younger ones, maybe 
in their fifties or younger, looking to go on holiday. 
(RN3 – ranked in column 5)
The third least important items ranked in position 30 by 
PTPs was ‘Will expenses be reimbursed?’ and again refer-
enced their health as taking precedent over expenses, 
but it may be important dependent on contribution. 
However, RNs ranked this statement in position 18 based 
on real examples of patients being out of pocket and this 
impacting on recruitment.
That’s less important for me, mostly because I 
wouldn’t perceive much in the way of expenses for 
myself for anything, because I live near the city centre 
and walk most places… I wouldn’t have thought – un-
less the study happened to be in another city or any-
thing like that – that I would have far to go. (PTP10 
– ranked in column 8)
But they [patients] are thinking, and I know the study 
I’m involved at the moment is involving extra visits 
for the patients, and I’m expecting that to be a bit of 
a hurdle if there’s not a budget for these extra visits 
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and parking outside the hospital and things like that. 
(RN7 – ranked in column 5)
RNs ranked ‘Who has approved the study?’ as the least 
important statement in position 32 and in comparison 
PTPs ranked this statement in position 17. Collectively, 
RNs seemed to think this was important information for 
professionals but not for PTPs yet the PTP group placed 
this higher suggesting it is of value.
… whenever I have been consenting somebody 
and said where the approvals are from or anything, 
there’s not really any interest at all. (RN1 – ranked in 
column 9)
I know there’s a whole process involved for these 
things so I wouldn’t want to see and I wouldn’t really 
need to know. I would assume it had been properly 
approved. (PTP1 – ranked in column 5)
The second least important items ranked by RNs in 
position 31 was ‘How have patients and the public been 
involved in the design of the study?’ with PTPs ranking 
this items at position 26. Both groups recognised the 
importance of the contribution of patients and the public 
(although it was not clear if the PTP group fully under-
stood what this item meant) but thought other aspects 
were more important.
… I don’t think patients think about that… I don’t 
think it’s of any relevance to them… its obviously im-
portant because for a study to work then it has to be 
in research for a reason and if you have patients in-
volved in the design of it then compliance rates are 
going to be better. (RN2 – ranked in column 9)
Yeah, I’d be interested in knowing that but I don’t 
think I would immediately want to know how the 
study had been put together. (PTP9 – ranked in col-
umn 7)
The RNs ranked ‘Has the scientific quality of study 
been checked?’ as the third least important statement 
in position 30 largely because in their experience this is 
not raised as a concern by patients. Interestingly, PTPs 
ranked this in position 11 stating that these quality checks 
on research were important. These  items had one of the 
largest variations in ranking between the groups and the 
largest difference between the groups across the top and 
bottom three (difference  of 19 ranked position (median 
score difference of 3.5 (PTP =  4.5 vs RN =  8)). 
Never had any questions about that. I have had pa-
tients or relatives who are well educated, they would 
want to know the purpose of the study but they would 
not… They don’t want to know overall how many 
people you require, its more about whether we have 
any experience doing this thing. (RN5 – ranked in 
column 9)
I think that would be very important to know. I know 
there’s all sorts of rules about what’s a good sample 
size and things like that, you know, so I would like 
to be able to access that information. It wouldn’t be 
as important, I think, as the other things I’ve ranked 
highly, but it would be more important. (PTP20 – 
ranked in column 5)
Items exhibiting variability on rank order between groups
Figure 1 illustrates the differences between stakeholder 
groups with regard to median ranking values of infor-
mational items ranging from most to least importance. 
As stated previously, items with a median difference 
greater than or equal to 2 rank points were considered 
to have significant variability between the individual 
groups. Table 4 lists each of the items that exhibited vari-
ability in median rank order between the stakeholder 
groups. Overall, 10 of the 32 items exhibited variability 
(predefined at ≥2 median scores difference) between the 
two stakeholder groups on rank order scores. The item 
with the largest median score rank ordered difference 
between the PTP and RN group was ‘Has the scientific 
quality of study been checked?’ As mentioned previ-
ously, there was a 3.5 median score difference between 
the groups (PTP=4.5 vs RN=8) with PTP ranking it at 
number 11 and RNs at position 32. One RN provided the 
following feedback on the exercise, which may provide 
some explanation as to why differences between the two 
groups were evident.
What I probably found hard is putting myself maybe 
say in the patients’ shoes, because you can think of it 
from, you know, very much like, you know, your role 
as from a nursing perspective, so yeah, always think-
ing about the patient. (RN4)
Missing information
On completion of the Q-sort interview, the PTP group 
were asked whether they felt any information items were 
missing from the card-sort set. The general consensus 
was that no additional information items were required, 
although three participants made suggestions as to addi-
tional information they might like to see in a PIL, namely, 
contact with other patients taking part in the trial; child-
care arrangements; and side-by-side comparison between 
standard care and trial interventions.
Contact with other patients taking part in the trial
It would be more likely, I think, in some ways, that 
I would like to have contact because I would…. You 
know, I think I would appreciate sharing experiences, 
and I don’t know… just thinking about it that might 
be something that would be useful for the study as 
well. (PTP10)
Childcare arrangements
So a logistical question I think is something that I 
would probably think… it would make me more posi-
tive towards something if it said there are facilities for 
childcare here or there’s a crèche or something like 
that, then it would make me think, ‘Oh, well, I can 
definitely do that then’. (PTP2)
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Side-by-side comparison between standard care and trial 
interventions
Maybe exactly what it would entail weighed up 
against… you know, showing the two side-by-side. 
This will entail having to come to hospital every week 
to get bloods, whereas normally you would never 
have to go and get… how time consuming it would be 
would probably be quite an important one. (PTP7)
Minimum information requirement for decision making
On completion of the Q-sort, we asked each of the PTP 
group if they could indicate at which point they felt they 
would have enough information to make a decision about 
taking part in the hypothetical RCT. The median number 
of cards required by the PTP group to make a decision 
was 14 with a range of 5–32. For the majority of the PTP 
group (60% of PTPs), a decision would be made that they 
Figure 1 Median importance scores: comparisons between potential trial participants and research nurses. GP, general 
practitioner; RN, research nurse.
Table 4 Items exhibiting significant variability on median rank order between stakeholder groups
Statement
Median 
difference
Median score Item rank position
PTP RN PTP RN
1 Has the scientific quality of study been checked? 3.5 4.5 8 11 32
2 Will expenses be reimbursed? 3 8 5 30 18
3 Will there be any impact on any insurance policies? 3 8 5 31 17
4 Who has approved the study? 3 5 8 17 32
5 Why have I been invited? 2.5 6 3.5 22 10
6 Do I have to take part? 2.5 5.5 3 18 7
7 What is the purpose of this study? 2 4 2 9 2
8 Will I receive any payments for taking part? 2 8 6 32 23
9 How have patients and the public been involved in the 
design of the study?
2 6 8 26 31
10 Who has overall responsibility for the study? 2 5 7 16 27
PTP, potential trial participant; RN, research nurse.
 o
n
 10 Septem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023303 on 5 September 2018. Downloaded from 
10 Innes K, et al. BMJ Open 2018;8:e023303. doi:10.1136/bmjopen-2018-023303
Open access 
had enough information using between 8 and 15 cards 
(25%–47% of the 32 statements).
Interpretation of context
An additional finding from the ‘think aloud’ interview 
data relates to participants interpretation of the specific 
context of the phase III trial described in the vignette. 
Although no reference to specific interventions was given 
apart from ‘treatment’, the majority of participants inter-
preted the setting to be a drug trial. Examples of this 
belief were evidenced across both groups.
My reason is that I just think if you were going to take 
something that was… if it was going to be taking med-
ication or if it was going to be some other sort of new 
treatment, it would be important to know as much as 
you could about what possibly might go wrong with 
it. (PTP20)
… So if people getting drug A are clinically much 
better than the people getting drug B and that’s 
evident quite early on when people would be 
expected to stop and move on to… (RN2)
DIsCussIOn
Principal findings
We believe this study to be one of the first to provide 
evidence in relation to how important PTPs and RNs 
perceive the informational items prescribed in the regu-
latory guidance to be with regard to making an informed 
choice about RCT participation. Our study used a novel 
methodology in this context (trials methodology) to 
obtain rankings of informational items for PILs from 
different trial stakeholder groups, namely PTPs and RNs. 
Previous research evidencing the relative importance of 
items included in trial PILs across different stakeholder 
groups is limited. Existing research on trial PILs has 
largely assumed the regulatory guidance reflects what 
potential participants actually want to know and has 
focused on areas such as structure, content or mode of 
delivery.8–10 Our study shows that more work is required 
to first define what information PTPs need (and/or want) 
to support an informed choice about participation.
Several of the statements identified as being most 
important relate to information about consequences 
of participation, namely disadvantages or advantages. 
Our results are, perhaps, not surprising given various 
decision-making theories and frameworks suggest that 
weighing up the pros and cons of a situation is a key 
component of decision making.15 In addition, several 
reports in the literature from qualitative studies that 
have explored participants’ reasons for participation (or 
not) in RCTs cite potential advantages or disadvantages 
of the trial as being influential.16 17 However, it may be 
important to further consider the context of the trial 
with regard to relative importance of items. The use of 
the vignette revealed that although not specified, partic-
ipants in our study believed the trial to be a drug trial, 
which may have influenced how they rated the relative 
importance of items.
Our results highlight that stakeholder groups were 
more similar when considering the most important items 
and that much more variability was exhibited between 
the groups with regard to the statements considered to 
be least important. Similar work exploring the impor-
tance of informational items included in a decision 
support intervention for trial participation also identified 
differences between stakeholder groups on key items.18 
In particular, items describing the advantages or disad-
vantages of non-participation (eg, forgoing access to 
trial intervention) in a trial showed more variation than 
others.18 An additional study has also evidenced vari-
ability among stakeholder groups with regard to content 
and mode of delivery of information provided to partici-
pants to support decisions about trial participation.19 The 
differences between stakeholders in perceived impor-
tance of information for trial participation decisions is of 
concern given much of the decision about participation is 
supported through conversations, which may or may not 
talk to a PTP’s main concerns, depending on who leads 
that conversation. The coverage of trial topics depending 
on who leads the conversation has been observed in 
recruitment consultations for a prostate cancer trial and 
had implications for recruitment and acceptance of allo-
cation.20 It is also possible that in practice some RNs adapt 
their conversation to be responsive to the needs of indi-
vidual patients and their concerns and preferences for 
information. Therefore, further research to unpack why 
differences between stakeholder groups exist and efforts 
to reduce these differences are important.
The majority of potential participants in our study 
revealed they would have made a decision about trial 
participation based on the information items they placed 
within the first 3–4 most important columns (around 8–15 
cards out of 32 and equal to around 47% of the informa-
tion specified in the HRA guidance). This suggests that 
all of the information that is included in a PIL may not 
be necessary for potential participants to make a decision 
about taking part in the trial. In further support of this, 
a study that explored the preferred length of the partici-
pant information sheet for research showed that 77% of 
participants chose to access only the first level of infor-
mation (less than that which may be contained on a stan-
dard PIL) before making a decision about participation.21 
In terms of the content of the minimum information set 
that potential participants deemed sufficient for decision 
making, our study showed they focused on statements 
related to the interventions (and any associated conse-
quences) rather than the formalities of the research. 
These findings are similar to Sand et al,22 who showed 
that the statements participants valued most were largely 
related to the study treatment and study-related activi-
ties rather than information on storage of data. Whether 
these key decision statements should be ordered such 
that they are represented first in PILs requires further 
research.
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As mentioned previously, a systematic review identi-
fied little evidence of what information potential partic-
ipants want to know when making a decision about 
research participation. Evidence could only be identi-
fied, from included studies, for less than half of the items 
the HRA suggest should be consideration for inclusion 
in PILs for research.6 While this review focused more 
broadly on research studies, not just trials, it further illus-
trates the point that the information provided in PILs 
falls short of being actually grounded in the informa-
tional needs and desires of those for whom it should be 
designed. This begs the question of who these patient-
facing documents are actually written for. Armstrong 
et al7 conducted a study to explore the function of PILs in 
which they concluded ‘PILs are the outcome of a process 
of institutional scripting that is strongly shaped by the 
accountability demands inherent in the ethical review 
process’. They go on to suggest that the content and text 
of a PIL is agreed between the trialist (the author of the 
PIL) and the Research Ethics Committee (REC).7 This 
lack of recognition of the audience of PILs is further 
evidenced when comparing PILs for RCTs to other infor-
mation resources shown to support decision making for 
treatment and screening decisions (so-called decision 
aids).23 PILs were shown to lack information deemed 
necessary to support good quality decision making.23 
Interestingly, in our study, the PTP group raised ‘contact 
with other participants’ and a ‘side-by-side comparison 
of trial treatment and standard care’ as being missing 
from the current information set. Both of these items are 
suggested as components of decision aids and to be useful 
for PTPs decision making.23 Perhaps it is time to review 
the guidance documents available to researchers to 
ensure that PILs are written specifically with the needs/
wishes of the target audience, the PTP, in mind and that 
the information more supports informed choices about 
trial participation with less focusing on institutional 
accountability.
When patients get involved in the design of research 
studies, they are frequently asked to help to improve 
the participant information. There is evidence to show 
that as potential participants, they can help to make 
the language clearer and easier to understand and not 
discriminatory or stigmatising.24 They can also help to 
present and deliver the information in ways that reflect 
the needs of participants and are culturally appropriate 
and sensitive.25 There is evidence that involving patients 
can also help to ensure that the content covers some 
important aspects of what potential participants want 
to know but not by systematically examining the infor-
mation prescribed in national guidance as in the study 
reported here.26 In this study, both the PTPs and RNs 
gave a low ranking to the statement about the involve-
ment of patients and the public in the design of the 
study. This is not surprising because the statement did 
not give any indication how the involvement might have 
helped PTPs make an informed decision whether to 
participate.
Evidence from research on information to support the 
informed consent process is needed by the trials commu-
nity. A recent prioritisation exercise to identify the top 
10 research priorities for recruitment in trials identified 
three priorities in the top 10 that could consider aspects 
of information provision in their scope.27 Specifically: 
priority 2. What information should trialists communicate 
to members of the public who are being invited to take 
part in a randomised trial in order to improve recruit-
ment to the trial?; priority 4. What are the best approaches 
for designing and delivering information to members of 
the public who are invited to take part in a randomised 
trial?; and priority 9. What are the best approaches to 
optimise the informed consent process when recruiting 
participants to randomised trials?27 This prioritisation (by 
a range of stakeholders including patients) of multiple 
questions around information to support the informed 
consent process to trials further highlights the need for 
additional research to identify models of best practice.
strengths and limitations
The sample included in this work is relatively small 
(n=20) and limited by geographic location. Identifying 
PTPs through the SHARE database was a straightfor-
ward, cost-effective and time-saving method; however, 
it is worth giving consideration to the type of people 
who have signed up to this database. Those who sign 
up to the SHARE register are likely to have an interest 
in research, perhaps making the sample somewhat 
dissimilar from the general public. The type of infor-
mation these participants value (or do not value) may 
differ given their existing experience of research or 
a more general awareness of research participation. 
While we have no reason to believe the locality would 
influence the results, it would be important to extend 
both the sample size, geographic spread and repre-
sentation from other stakeholder groups.
Although the vignette was worded slightly differently 
for each stakeholder group, it was used to try and ensure 
that the study was interpreted in the same way for all 
participants. PTPs appeared to have no problems with 
the vignette as they were being asked to think about a 
decision from their own point of view. For the RN group, 
we were asking them to think about what potential partic-
ipants thought, and this proved more challenging for the 
RNs. As such, the vignettes between the two groups were 
slightly different, most notably in the RN group through 
the use of phrasing around comparing treatments, which 
was lacking from the PP group. Therefore, it must also 
be considered that this difference could have influenced 
preferences for information. Although the vignette talked 
about treatments—treatment ‘a’ and treatment ‘b’—for a 
chronic condition, many participants interpreted this as 
two drug treatments. It is worth considering the possibility 
that this may have had an impact on how the statements 
were ranked. For example, information relating to side 
effects, and risks and disadvantages may be deemed more 
pertinent for people considering participation in a drug 
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trial (especially if it were a new product) compared with 
a trial of non-drug interventions. Further exploration of 
different aspects of trial design (including different inter-
ventions) and how this influences preferences for infor-
mation is needed. Indeed, the purposive exploration of 
a range of vignettes that describe different contextual 
aspects of the trial (eg, uncertainty surrounding each 
intervention and the risk/benefit profiles for each) 
would be important to further consider whether context 
plays a role. Another potential limitation with regard to 
interpretation relates to the Q-sort statements. Although 
prompts were developed if participants struggled with 
interpretation, the statements for the Q-Sort were all 
quite short and therefore their meaning was open to a 
certain amount of interpretation. The meaning of each 
statement and how clear it is may have had a bearing on 
what the participants understand by it and how important 
they think it is.
A significant strength of this study was the use 
of the Q-methodology providing both qualitative 
and quantitative data to investigate how important 
different stakeholder groups perceived the informa-
tional items to be. The use of Q-methodology in trials 
methodology research is not common, but the data it 
produces yield novel insights not easily produced by 
other methods.28
COnClusIOn
In conclusion, this study has provided a unique insight 
into how and why different trial stakeholder groups rank 
informational items contained within PILs for RCTs. This 
study has shown that both PTPs and RNs ranked similar 
statements as being most important, yet clear differ-
ences exist in the ranking of the least important state-
ments. These results have implications for researchers 
developing PILs for RCTs. Patient information leaflets 
are directed at PTPs and should therefore, by default, 
include information that PTPs want and need to make an 
informed choice about participation in a trial. Additional 
efforts to work in parallel with PTPs to identify the infor-
mation considered critical to support informed choices 
about trial participation is needed.
Acknowledgements The authors would like to thank the stakeholders who 
participated in the study for their time. 
Contributors KG was responsible for conceiving the study. KI, SC, MKC and KG 
designed the study. KI conducted the data collection and statistical analysis. KG and 
KI conducted the qualitative analysis. KG and KI led the writing of the manuscript. 
SC, MKC and JE contributed to further drafts of the manuscript. All authors read and 
approved the final manuscript. 
Funding This work was supported by personal fellowship award (to KG) from 
the Medical Research Council Strategic Skills Methodology Fellowship (MRC MR/
L01193X/1). KI and SC were supported by awards from the National Institute for 
Health Research Health Technology Assessment Programme (HTA ref 14/192/71, 
HTA ref 11/58/15). The Health Services Research Unit is supported by a core grant 
from the Chief Scientist Office of the Scottish Government Health and Social Care 
Directorates. 
Competing interests None declared.
Patient consent Not required.
ethics approval The study was approved by NRES Committee London – Bromley 
(Rec ref: 15/LO/1221) and NHS Grampian Research and Development department 
(R&D ref: 2015UA013). 
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No database available.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
reFerenCes
 1. Pocock SJ. Clinical trials - a practical approach. New Jersey: John 
Wiley & Sons Ltd, 1983.
 2. NHS Choices. Clinical Trials and medical research - Ethics 
committees. http://www. nhs. uk/ conditions/ clincial- trials/ Pages/ 
Ethicscommittees. aspx (accessed 09 Mar 2018).
 3. WMA - World Medical Association. WMA Declaration of Helsinki - 
ethical principles for medical research involving human subjects. 
http://www. wma. net/ en/ 30publications/ 10policies/ b3/ (accessed 09 
Mar 2018).
 4. EU directive 2011/20/EC. 2004 https:// ec. europa. eu/ health/ sites/ 
health/ files/ files/ eudralex/ vol- 1/ reg_ 2014_ 536/ reg_ 2014_ 536_ en. pdf 
(accessed 09 Mar 2018).
 5. NHS. Informing participants and seeking consent. https://www. hra. 
nhs. uk/ planning- and- improving- research/ best- practice/ informing- 
participants- and- seeking- consent/ (accessed 09 Mar 2018).
 6. Kirkby HM, Calvert M, Draper H, et al. What potential research 
participants want to know about research: a systematic review. BMJ 
Open 2012;2:e000509.
 7. Armstrong N, Dixon-Woods M, Thomas A, et al. Do informed 
consent documents for cancer trials do what they should? A study of 
manifest and latent functions. Sociol Health Illn 2012;34:1230–45.
 8. Nishimura A, Carey J, Erwin PJ, et al. Improving understanding in 
the research informed consent process: a systematic review of 54 
interventions tested in randomized control trials. BMC Med Ethics 
2013;14:28.
 9. Sand K, Kaasa S, Loge JH. The understanding of informed consent 
information—definitions and measurements in empirical studies. 
AJOB Prim Res 2010;1:4–24.
 10. Flory J, Emanuel E. Interventions to improve research participants' 
understanding in informed consent for research: a systematic review. 
JAMA 2004;292:1593–601.
 11. Watts S. Doing Q methodological research: theory, method and 
interpretation. London: SAGE, 2012.
 12. Langston AL, Campbell MK, Entwistle VA, et al. A centralised public 
information resource for randomised trials: a scoping study to 
explore desirability and feasibility. BMC Health Serv Res 2005;5:39.
 13. https://www. registerforshare. org/
 14. Bryman A. Business research methods. Bell, Emma-1968. 3rd ed. 
Cambridge: Oxford University Press, 2011. ISBN 9780199583409. 
OCLC 746155102.
 15. Durand MA, Stiel M, Boivin J, et al. Where is the theory? Evaluating 
the theoretical frameworks described in decision support 
technologies. Patient Educ Couns 2008;71:125–35.
 16. McCann S, Campbell M, Entwistle V. Recruitment to clinical trials: a 
meta-ethnographic synthesis of studies of reasons for participation. 
J Health Serv Res Policy 2013;18:233–41.
 17. McCann SK, Campbell MK, Entwistle VA. Reasons for participating in 
randomised controlled trials: conditional altruism and considerations 
for self. Trials 2010;11:31.
 18. Gillies K, Skea ZC, MacLennan SJ, et al. Determining information 
for inclusion in a decision-support intervention for clinical trial 
participation: a modified Delphi approach. Clin Trials 2013;10:967–76.
 19. Gillies K, Skea ZC, Campbell MK. Decision aids for randomised 
controlled trials: a qualitative exploration of stakeholders' views. BMJ 
Open 2014;4:e005734.
 20. Wade J, Donovan JL, Lane JA, et al. It's not just what you say, it's 
also how you say it: opening the 'black box' of informed consent 
appointments in randomised controlled trials. Soc Sci Med 
2009;68:2018–28.
 21. Antoniou EE, Draper H, Reed K, et al. An empirical study on the 
preferred size of the participant information sheet in research. J Med 
Ethics 2011;37:557–62.
 o
n
 10 Septem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023303 on 5 September 2018. Downloaded from 
13Innes K, et al. BMJ Open 2018;8:e023303. doi:10.1136/bmjopen-2018-023303
Open access
 22. Sand K, Loge JH, Berger O, et al. Lung cancer patients' perceptions 
of informed consent documents. Patient Educ Couns 2008;73:313–7.
 23. Gillies K, Huang W, Skea Z, et al. Patient information leaflets (PILs) 
for UK randomised controlled trials: a feasibility study exploring 
whether they contain information to support decision making about 
trial participation. Trials 2014;15:62.
 24. Donovan J, Mills N, Smith M, et al. Quality improvement report: 
Improving design and conduct of randomised trials by embedding 
them in qualitative research: ProtecT (prostate testing for cancer and 
treatment) study. Commentary: presenting unbiased information to 
patients can be difficult. BMJ 2002;325:766–70.
 25. Staley K, Ashcroft J, Doughty L, et al. Making it clear and  
relevant: patients and carers add value to studies through research 
document reviews. Mental Health and Social Inclusion  
2016;20:36–43.
 26. Knapp P, Raynor DK, Silcock J, et al. Performance-based readability 
testing of participant materials for a phase I trial: TGN1412. J Med 
Ethics 2009;35:573–8.
 27. Healy P, Galvin S, Williamson PR, et al. Identifying trial recruitment 
uncertainties using a James Lind Alliance Priority Setting Partnership 
- the PRioRiTy (Prioritising Recruitment in Randomised Trials) study. 
Trials 2018;19:147.
 28. Protière C, Spire B, Mora M, et al. Patterns of patient and healthcare 
provider viewpoints regarding participation in HIV cure-related 
clinical trials. Findings from a multicentre French survey using Q 
methodology (ANRS-APSEC). PLoS One 2017;12:e0187489.
 o
n
 10 Septem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023303 on 5 September 2018. Downloaded from 
